Loading…
Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review
Pneumococcal disease (PD), caused by , is a serious global health issue, primarily for adults over 65, due to its high mortality and morbidity rates. Recently, broader-serotype vaccines have been introduced to cope with tremendous hospital costs and decreasing quality of life. Our study aims to syst...
Saved in:
| Published in: | Healthcare (Basel) 2024-12, Vol.12 (23), p.2490 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | 23 |
| container_start_page | 2490 |
| container_title | Healthcare (Basel) |
| container_volume | 12 |
| creator | Vo, Nam Xuan Pham, Huong Lai Bui, Uyen My Ho, Han Tue Bui, Tien Thuy |
| description | Pneumococcal disease (PD), caused by
, is a serious global health issue, primarily for adults over 65, due to its high mortality and morbidity rates. Recently, broader-serotype vaccines have been introduced to cope with tremendous hospital costs and decreasing quality of life. Our study aims to systematically review the cost-effectiveness of current PCVs (pneumococcal conjugate vaccines) and PPVs (pneumococcal polysaccharide vaccine) from 2018 to April 2024.
Articles were identified through PubMed, Embase, and Cochrane. Key outcomes include an improved incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY), with the article's quality assessed via the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022). In total, 23 studies were included, with 22 studies of high quality and 1 of moderate quality.
These articles showed that PCV20 was the most cost-effective option compared with other vaccines, including PPV23, PCV13, PCV15, and PCV15/PPV23, for both young and older adults, regardless of risk factors. PCV20, when used alone, saved greater costs than PCV20, followed by PPV23.
For countries applying lower-valency vaccines, switching to PCV20 as a single regimen would be the most beneficial for averting pneumococcal cases and reducing costs in adults aged 18-64 and over 65. |
| doi_str_mv | 10.3390/healthcare12232490 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11641157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A819950726</galeid><sourcerecordid>A819950726</sourcerecordid><originalsourceid>FETCH-LOGICAL-g336t-dfeecf0cae52f4e9faa9d2af40e389fa3c30371ec91b9751809c240a3ceec8253</originalsourceid><addsrcrecordid>eNptkU1PXSEQhompUaP-gS4MSTfdHAvM-cJNc3NjPxITTb82XRDkDPdiOHB74Fzjvy-2ttVGZgEz88xL3gwhLzk7BZDszRq1z2ujJ-RCgKgl2yEHQoiukgzEi0fvfXKc0g0rR3Loodkj-yDbvuFcHJDvy5hydW4tmuy2GDAlGi3Na6RXAecxmmiM9vSbNsYFpC786i2G2Wd6FTez19nFcEYX9PNdyjiW1NBPuHV4e0R2rfYJjx_uQ_L13fmX5Yfq4vL9x-XioloBtLkaLKKxzGhshK1RWq3lILStGUJfMjDAoONoJL-WXcN7Jo2oWamXuV40cEje_tbdzNcjDgZDnrRXm8mNerpTUTv1tBPcWq3iVnHe1pw3XVF4_aAwxR8zpqxGlwx6rwPGOSngdSt528i-oK_-Q2_iPIXi754CKTjv4B-10h6VCzaWj829qFr0XMqGdaIt1OkzVIkBR2diQOtK_cnAyWOnfy3-2Sf8BEWapLM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3143921173</pqid></control><display><type>article</type><title>Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Vo, Nam Xuan ; Pham, Huong Lai ; Bui, Uyen My ; Ho, Han Tue ; Bui, Tien Thuy</creator><creatorcontrib>Vo, Nam Xuan ; Pham, Huong Lai ; Bui, Uyen My ; Ho, Han Tue ; Bui, Tien Thuy</creatorcontrib><description>Pneumococcal disease (PD), caused by
, is a serious global health issue, primarily for adults over 65, due to its high mortality and morbidity rates. Recently, broader-serotype vaccines have been introduced to cope with tremendous hospital costs and decreasing quality of life. Our study aims to systematically review the cost-effectiveness of current PCVs (pneumococcal conjugate vaccines) and PPVs (pneumococcal polysaccharide vaccine) from 2018 to April 2024.
Articles were identified through PubMed, Embase, and Cochrane. Key outcomes include an improved incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY), with the article's quality assessed via the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022). In total, 23 studies were included, with 22 studies of high quality and 1 of moderate quality.
These articles showed that PCV20 was the most cost-effective option compared with other vaccines, including PPV23, PCV13, PCV15, and PCV15/PPV23, for both young and older adults, regardless of risk factors. PCV20, when used alone, saved greater costs than PCV20, followed by PPV23.
For countries applying lower-valency vaccines, switching to PCV20 as a single regimen would be the most beneficial for averting pneumococcal cases and reducing costs in adults aged 18-64 and over 65.</description><identifier>ISSN: 2227-9032</identifier><identifier>EISSN: 2227-9032</identifier><identifier>DOI: 10.3390/healthcare12232490</identifier><identifier>PMID: 39685112</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adults ; Aged ; Cost analysis ; Disease ; Economic analysis ; Economic aspects ; Evaluation ; Health aspects ; Intervention ; Medical care, Cost of ; Mortality ; Older people ; Pathogens ; Pediatrics ; Pneumococcal infections ; Pneumococcal vaccine ; Pneumonia ; Prevention ; Streptococcus infections ; Systematic Review ; Vaccines ; Willingness to pay</subject><ispartof>Healthcare (Basel), 2024-12, Vol.12 (23), p.2490</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0009-0008-4154-8415 ; 0009-0004-3461-223X ; 0009-0002-0065-6803 ; 0000-0002-1406-7949</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3143921173/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3143921173?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39685112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vo, Nam Xuan</creatorcontrib><creatorcontrib>Pham, Huong Lai</creatorcontrib><creatorcontrib>Bui, Uyen My</creatorcontrib><creatorcontrib>Ho, Han Tue</creatorcontrib><creatorcontrib>Bui, Tien Thuy</creatorcontrib><title>Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review</title><title>Healthcare (Basel)</title><addtitle>Healthcare (Basel)</addtitle><description>Pneumococcal disease (PD), caused by
, is a serious global health issue, primarily for adults over 65, due to its high mortality and morbidity rates. Recently, broader-serotype vaccines have been introduced to cope with tremendous hospital costs and decreasing quality of life. Our study aims to systematically review the cost-effectiveness of current PCVs (pneumococcal conjugate vaccines) and PPVs (pneumococcal polysaccharide vaccine) from 2018 to April 2024.
Articles were identified through PubMed, Embase, and Cochrane. Key outcomes include an improved incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY), with the article's quality assessed via the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022). In total, 23 studies were included, with 22 studies of high quality and 1 of moderate quality.
These articles showed that PCV20 was the most cost-effective option compared with other vaccines, including PPV23, PCV13, PCV15, and PCV15/PPV23, for both young and older adults, regardless of risk factors. PCV20, when used alone, saved greater costs than PCV20, followed by PPV23.
For countries applying lower-valency vaccines, switching to PCV20 as a single regimen would be the most beneficial for averting pneumococcal cases and reducing costs in adults aged 18-64 and over 65.</description><subject>Adults</subject><subject>Aged</subject><subject>Cost analysis</subject><subject>Disease</subject><subject>Economic analysis</subject><subject>Economic aspects</subject><subject>Evaluation</subject><subject>Health aspects</subject><subject>Intervention</subject><subject>Medical care, Cost of</subject><subject>Mortality</subject><subject>Older people</subject><subject>Pathogens</subject><subject>Pediatrics</subject><subject>Pneumococcal infections</subject><subject>Pneumococcal vaccine</subject><subject>Pneumonia</subject><subject>Prevention</subject><subject>Streptococcus infections</subject><subject>Systematic Review</subject><subject>Vaccines</subject><subject>Willingness to pay</subject><issn>2227-9032</issn><issn>2227-9032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNptkU1PXSEQhompUaP-gS4MSTfdHAvM-cJNc3NjPxITTb82XRDkDPdiOHB74Fzjvy-2ttVGZgEz88xL3gwhLzk7BZDszRq1z2ujJ-RCgKgl2yEHQoiukgzEi0fvfXKc0g0rR3Loodkj-yDbvuFcHJDvy5hydW4tmuy2GDAlGi3Na6RXAecxmmiM9vSbNsYFpC786i2G2Wd6FTez19nFcEYX9PNdyjiW1NBPuHV4e0R2rfYJjx_uQ_L13fmX5Yfq4vL9x-XioloBtLkaLKKxzGhshK1RWq3lILStGUJfMjDAoONoJL-WXcN7Jo2oWamXuV40cEje_tbdzNcjDgZDnrRXm8mNerpTUTv1tBPcWq3iVnHe1pw3XVF4_aAwxR8zpqxGlwx6rwPGOSngdSt528i-oK_-Q2_iPIXi754CKTjv4B-10h6VCzaWj829qFr0XMqGdaIt1OkzVIkBR2diQOtK_cnAyWOnfy3-2Sf8BEWapLM</recordid><startdate>20241209</startdate><enddate>20241209</enddate><creator>Vo, Nam Xuan</creator><creator>Pham, Huong Lai</creator><creator>Bui, Uyen My</creator><creator>Ho, Han Tue</creator><creator>Bui, Tien Thuy</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0008-4154-8415</orcidid><orcidid>https://orcid.org/0009-0004-3461-223X</orcidid><orcidid>https://orcid.org/0009-0002-0065-6803</orcidid><orcidid>https://orcid.org/0000-0002-1406-7949</orcidid></search><sort><creationdate>20241209</creationdate><title>Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review</title><author>Vo, Nam Xuan ; Pham, Huong Lai ; Bui, Uyen My ; Ho, Han Tue ; Bui, Tien Thuy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g336t-dfeecf0cae52f4e9faa9d2af40e389fa3c30371ec91b9751809c240a3ceec8253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adults</topic><topic>Aged</topic><topic>Cost analysis</topic><topic>Disease</topic><topic>Economic analysis</topic><topic>Economic aspects</topic><topic>Evaluation</topic><topic>Health aspects</topic><topic>Intervention</topic><topic>Medical care, Cost of</topic><topic>Mortality</topic><topic>Older people</topic><topic>Pathogens</topic><topic>Pediatrics</topic><topic>Pneumococcal infections</topic><topic>Pneumococcal vaccine</topic><topic>Pneumonia</topic><topic>Prevention</topic><topic>Streptococcus infections</topic><topic>Systematic Review</topic><topic>Vaccines</topic><topic>Willingness to pay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vo, Nam Xuan</creatorcontrib><creatorcontrib>Pham, Huong Lai</creatorcontrib><creatorcontrib>Bui, Uyen My</creatorcontrib><creatorcontrib>Ho, Han Tue</creatorcontrib><creatorcontrib>Bui, Tien Thuy</creatorcontrib><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Healthcare (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vo, Nam Xuan</au><au>Pham, Huong Lai</au><au>Bui, Uyen My</au><au>Ho, Han Tue</au><au>Bui, Tien Thuy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review</atitle><jtitle>Healthcare (Basel)</jtitle><addtitle>Healthcare (Basel)</addtitle><date>2024-12-09</date><risdate>2024</risdate><volume>12</volume><issue>23</issue><spage>2490</spage><pages>2490-</pages><issn>2227-9032</issn><eissn>2227-9032</eissn><abstract>Pneumococcal disease (PD), caused by
, is a serious global health issue, primarily for adults over 65, due to its high mortality and morbidity rates. Recently, broader-serotype vaccines have been introduced to cope with tremendous hospital costs and decreasing quality of life. Our study aims to systematically review the cost-effectiveness of current PCVs (pneumococcal conjugate vaccines) and PPVs (pneumococcal polysaccharide vaccine) from 2018 to April 2024.
Articles were identified through PubMed, Embase, and Cochrane. Key outcomes include an improved incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY), with the article's quality assessed via the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022). In total, 23 studies were included, with 22 studies of high quality and 1 of moderate quality.
These articles showed that PCV20 was the most cost-effective option compared with other vaccines, including PPV23, PCV13, PCV15, and PCV15/PPV23, for both young and older adults, regardless of risk factors. PCV20, when used alone, saved greater costs than PCV20, followed by PPV23.
For countries applying lower-valency vaccines, switching to PCV20 as a single regimen would be the most beneficial for averting pneumococcal cases and reducing costs in adults aged 18-64 and over 65.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39685112</pmid><doi>10.3390/healthcare12232490</doi><orcidid>https://orcid.org/0009-0008-4154-8415</orcidid><orcidid>https://orcid.org/0009-0004-3461-223X</orcidid><orcidid>https://orcid.org/0009-0002-0065-6803</orcidid><orcidid>https://orcid.org/0000-0002-1406-7949</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2227-9032 |
| ispartof | Healthcare (Basel), 2024-12, Vol.12 (23), p.2490 |
| issn | 2227-9032 2227-9032 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11641157 |
| source | Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
| subjects | Adults Aged Cost analysis Disease Economic analysis Economic aspects Evaluation Health aspects Intervention Medical care, Cost of Mortality Older people Pathogens Pediatrics Pneumococcal infections Pneumococcal vaccine Pneumonia Prevention Streptococcus infections Systematic Review Vaccines Willingness to pay |
| title | Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A41%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Effectiveness%20of%20the%20Pneumococcal%20Vaccine%20in%20the%20Adult%20Population:%20A%20Systematic%20Review&rft.jtitle=Healthcare%20(Basel)&rft.au=Vo,%20Nam%20Xuan&rft.date=2024-12-09&rft.volume=12&rft.issue=23&rft.spage=2490&rft.pages=2490-&rft.issn=2227-9032&rft.eissn=2227-9032&rft_id=info:doi/10.3390/healthcare12232490&rft_dat=%3Cgale_pubme%3EA819950726%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g336t-dfeecf0cae52f4e9faa9d2af40e389fa3c30371ec91b9751809c240a3ceec8253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3143921173&rft_id=info:pmid/39685112&rft_galeid=A819950726&rfr_iscdi=true |